Efficacy and Safety of Tetravalent Dengue Vaccines in Children and Adolescents: A Systematic Review of Phase 3 Randomized Controlled Trials
DOI:
https://doi.org/10.35730/1g8ywk15Keywords:
Dengue, vaccine, children, systematic review, randomized controlled trialAbstract
Background: Dengue is a major mosquito-borne disease in tropical countries, including Indonesia. Tetravalent dengue vaccines have been tested in large phase 3 randomized controlled trials (RCTs). This systematic review summarizes their efficacy and safety in children and adolescents.
Methods: Peer-reviewed phase 3 placebo-controlled RCTs of tetravalent dengue vaccines in children and adolescents, reporting virologically confirmed dengue, were eligible. Data were extracted and synthesized without meta-analysis, following the SWiM reporting guideline, with qualitative risk-of-bias appraisal using RoB 2 domains. Tables summarize eligibility (Table 1), trial characteristics (Table 2), serotype-specific efficacy (Table 3), TIDES follow-up (Table 4), and key findings (Table 5).
Findings: Three RCTs (CYD14, CYD15, TIDES; 51,243 randomized participants) were included. Vaccine efficacy against virologically confirmed dengue was 56.5% (95% CI 43.8–66.4) in CYD14, 60.8% (95% CI 52.0–68.0) in CYD15, and 80.2% (95% CI 73.3–85.3) in TIDES. Efficacy against hospitalized dengue was 80.3% in CYD15 and 95.4% (95% CI 88.4–98.2) in TIDES. Efficacy varied by serotype in CYD15. In published follow-up of TIDES, efficacy against symptomatic dengue was 61.2% at 54 months. Serious adverse events were similar between vaccine and placebo groups where reported.
Conclusion: Tetravalent dengue vaccines reduce symptomatic and hospitalized dengue in children and adolescents in endemic settings, with efficacy varying by vaccine, serotype, and population.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Nidianti Nerissa, Nana Sri Rahayu, Sri Mardlaniah (Author)

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.